Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
38,466,645
-
Total 13F shares
-
6,865,287
-
Share change
-
+562,943
-
Total reported value
-
$46,445,675
-
Price per share
-
$6.75
-
Number of holders
-
35
-
Value change
-
+$3,796,725
-
Number of buys
-
18
-
Number of sells
-
13
Institutional Holders of Protara Therapeutics, Inc. - Common Stock (TARA) as of Q4 2021
As of 31 Dec 2021,
Protara Therapeutics, Inc. - Common Stock (TARA) was held by
35 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,865,287 shares.
The largest 10 holders included
Opaleye Management Inc., ORBIMED ADVISORS LLC, VANGUARD GROUP INC, CITADEL ADVISORS LLC, PERCEPTIVE ADVISORS LLC, Ikarian Capital, LLC, DLD Asset Management, LP, BOXER CAPITAL, LLC, BAKER BROS. ADVISORS LP, and GOLDMAN SACHS GROUP INC.
This page lists
35
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.